Pitavastatin for the treatment of primary hyperlipidemia and mixed dyslipidemia

Expert Review of Cardiovascular Therapy

Volumn 8, Issue 8, 2010, Pages 1079-1090

  Gotto Jr , Antonio M ^a   Moon, Jennifer ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

cholesterol; coronary heart disease; dyslipidemia; HMG CoA reductase inhibitors; LDL; pitavastatin

Indexed keywords

ATAZANAVIR; ATORVASTATIN; CERIVASTATIN; COMPACTIN; CYCLOSPORIN; DIGOXIN; ENALAPRIL; ERYTHROMYCIN; EZETIMIBE; FENOFIBRATE; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ITRACONAZOLE; KETOCONAZOLE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICARDIPINE; PITAVASTATIN; PRAVASTATIN; PROTEINASE INHIBITOR; RIFAMPICIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; VERAPAMIL; WARFARIN; CYTOCHROME P450; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN RECEPTOR; QUINOLINE DERIVATIVE;

ATHEROSCLEROSIS; BACKACHE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG GLUCURONIDATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; GRAPEFRUIT JUICE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERLIPOPROTEINEMIA TYPE 3; HYPERTRIGLYCERIDEMIA; LIMB PAIN; MIXED DYSLIPIDEMIA; MUSCLE WEAKNESS; MYALGIA; NONHUMAN; PLEIOTROPY; POSTMARKETING SURVEILLANCE; PRIMARY HYPERLIPIDEMIA; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT; ANIMAL; COMPARATIVE STUDY; DRUG EFFECTS; DRUG INTERACTION; DYSLIPIDEMIAS; HYPERLIPIDEMIAS; METABOLISM; PATHOPHYSIOLOGY;

ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; DYSLIPIDEMIAS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; QUINOLINES; RECEPTORS, LDL;

EID: 77955188767     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.10.82     Document Type: Review

References (69)

1. Grundy SM, Cleeman JI, Merz CNB et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110, 227-239 (2004).
2. Robinson JG, Smith B, Maheshwari N, Schrott H. Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis. J. Am. Coll. Cardiol. 46, 1855-1862 (2005).
3. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA, 285,2486-2497(2001)
4. Cholesterol Treatment Trialists' Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366, 1267-1278 (2005).
5. Gotto AM. Contemporary Diagnosis and Management of Lipid Disorders (4th Edition). Handbooks in Health Care, PA, USA (2008).
6. Product information. Livalo (pitavastatin). Kowa Pharmaceuticals America, Inc., AL, USA (2009).
7. Suzuki M, Iwasaki H, Fujikawa Y et al. Synthesis and biological evaluations of quinoline-based HMG-CoA reductase inhibitors. Bioorg. Med. Chem. 9, 2727-2743 (2001).
8. Morikawa S, Umetani M, Nakagawa S et al. Relative induction of mRNA for HMG CoA reductase and LDL receptor by five different HMG-CoA reductase inhibitors in cultured human cells. J. Atheroscler. Thromb. 7(3), 138-144 (2000).
9. Kajinami K, Takekoshi N, Saito Y. Pitavastatin: efficacy and safety profiles of a novel synthetic HMG-CoA reductase inhibitor. Cardiovasc. Drug Rev. 21(3), 199-215 (2003).
10. Hirano M, Maeda K, Shitara, Sugiyama Y. Drug-drug interaction between pitavastatin and various drugs via OATP1B1. DrugMetab. Dispos. 34(7), 1229-1236 (2006).
11. Hirano M, Maeda K, Shitara Y, Sugiyama Y. Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J. Pharmacol. Exp. Ther. 311(1), 139-146 (2004).
12. Voora D, Shah SH, Spasojevic I et al. The SLCO1B15 genetic variant is associated with statin-induced side effects. J. Am. Coll. Cardiol. 54(17), 1609-1616 (2009).
13. SEARCH Collaborative Group. SLCO1B1 variants and statin-induced myopathy - a genome-wide study. N. Engl. J. Med. 359(8),789-799(2008).
14. Wen J, Xiong Y. OATP1B1 388A
15. Ieiri I, Suwannakul S, Maeda K et al. SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers. Clin. Pharmacol. Ther. 82(5), 541-547 (2007).
16. Hayashi T, Yokote K, Saito Y, Iguchi A. Pitavastatin: efficacy and safety in intensive lipid lowering. Exp. Opin. Pharmacother. 8, 2315-2327 (2007).
17. Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance.Clin. Pharmacol. Ther. 80(6),565-581(2006).
18. Shitara Y, Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol. Ther. 112(1), 71-105 (2006).
19. Fujino H, Saito T, Tsunenari Y, Kojima J. Interaction between several medicines and statins. Arzneimittelforschung 53(3), 145-153 (2003).
20. Ando H, Tsuroka S, Yanagihara H et al. Effects of grapefruit juice on the pharmacokinetics of pitavastatin and atorvastatin. Br. J. Clin. Pharmacol. 60(5), 494-497 (2005).
21. Wensel TM, Waldrop BA, Wensel B. Pitavastatin: a new HMG-CoA reductase inhibitor. Ann. Pharmacother. 144, 507-514 (2010).
22. Sakaeda T, Fujino H, Komoto C et al. Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1- mediated transport. Pharm. Res. 23(3), 502-512 (2005).
23. Prueksaritanont T, Subramanian R, Fang X et al. Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. DrugMetab. Disp. 30(5), 505-512 (2002).
24. Prueksaritanont T, Zhao J, Ma B et al. Mechanistic studies on metabolic interactions between gemfibrozil and statins. J. Pharm. Exp. Ther. 301(3), 1042-1051 (2002).
25. Prueksaritanont T, Tang C, Qui Y et al. Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab. Dispos. 30(11), 1280-1287 (2002).
26. Fujino H, Saito T, Tsunenari Y, Kojima J. Effect of gemfibrozil on the metabolism of pitavastatin - determining the best animal model for human CYP and UGT activities. DrugMetabol. Drug Interact. 20(1-2), 25-42 (2004).
27. Holtzman CW, Wiggins BS, Spinler SA. Role of p-glycoprotein in statin drug interactions. Pharmacotherapy 26(11), 1601-1607 (2006).
28. Wang E, Casciano CN, Clement RP, Johnson WW. HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein. Pharm. Res. 18(6), 800-806 (2001).
29. Fujino H, Yamada I, Shimada S, Kojima J. Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase - effect of cMOAT deficiency on hepatobiliary excretion in rats and of mdr1a/b gene disruption on tissue distribution in mice. Drug Metab. Pharmacokinet. 17(5), 449-456 (2002).
30. Inagaki Y, Hunt T, Arana B et al. Drug-drug interaction study to assess the effects of multiple dose of pitavastatin (Livalo®) on steady-state warfarin in healthy adult volunteers. XV International Symposium on Atherosclerosis 2009. 14-18 June 2009, Boston, MA, USA. Atheroscler. Suppl. 10(2), P493 (2009).
31. Kajinami K, Mabushi H, Saito Y. NK-104: a novel synthetic HMG-CoA reductase inhibitors. Exp. Opin. Invest. Drugs 9(11), 2653-2661 (2000).
32. Saito Y, Yamada N, Teramoto T et al. Clinical efficacy of pitavastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in patients with hyperlipidemia. Arzneimittelforschung 52, 251-255 (2002).
33. Saito Y, Yamada N, Teramoto T, Itakura H et al. A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia. Atherosclerosis 162(2), 373-379 (2002).
34. Kajinami K, Koizumi J, Ueda K et al.; Hokuriku NK-104 study group. Effects of NK-104, a new hydroxymethylglutaryl- coenzyme reductase inhibitor, on low-density lipoprotein cholesterol in heterozygous familial hypercholesterolemia. Am. J. Cardiol. 85(2), 178-183 (2000).
35. Noji Y, Higashikata T, Inazu A et al.; Hokuriku NK-104 study group. Long-term treatment with pitavastatin (NK-104), a new HMG-CoA reductase inhibitor, of patients with heterozygous familial hypercholesterolemia. Atherosclerosis 163(1), 157-164 (2002).
36. Sone H, Takahashi A, Shimano H et al. HMG-CoA reductase inhibitor decreases small dense low-density lipoprotein and remnant-like particle cholesterol in patients with Type 2 diabetes. Life Sci. 71(20), 2403-2412 (2002).
37. Park S, Kang HJ, Rim SJ et al. A randomized, open-label study to evaluate the efficacy and safety of pitavastatin compared with simvastatin in Korean patients with hypercholesterolemia. Clin. Ther. 27, 1074-1082 (2005).
38. Budinski D, Arneson V, Hounslow N, Gratsiansky N. Pitavastatin compared with atorvastatin in primary hypercholesterolemia or combined dyslipidemia. Clin. Lipidol. 4(3), 291-302 (2009).
39. Ose L, Budinski D, Hounslow N, Arneson V. Comparison of pitavastatin with simvastatin in primary hypercholesterolemia or combined dyslipidemia. Curr. Med. Res. Opin. 25(10), 2755-2764 (2009).
40. Kurihara Y, Douzono T, Kawakita K. A large-scale, long-term, prospective post-marketing surveillance of pitavastatin: LIVALO effectiveness and safety (LIVES) study. Jpn Pharmacol. Ther. 36(8), 709-731 (2008).
41. Teramoto T, Shimano H, Yokote K, Urashima M. New evidence on pitavastatin: efficacy and safety in clinical studies. Expert Opin. Pharmacother. 11(5), 817-828 (2010).
42. Yokote K, Bujo H, Hanaoka H et al. Multicenter collaborative randomized parallel group comparative study of pitavastatin and atorvastatin in Japanese hypercholesterolemic patients. Collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis prevention (CHIBA study). Atherosclerosis 201, 345-352 (2008).
43. Koshiyama H, Taniguchi A, Tanaka K et al.;Effects of pitavastatin on lipid profiles and high-sensitivity CRP in Japanese subjects with hypercholesterolemia: Kansai investigation of statin for hyperlipidemic intervention in metabolism and endocrinology (KISHIMEN) investigators. J. Atheroscler. Thromb. 15, 345-350(2008)
44. Sasaki J, Ikeda Y, Kuribayashi T et al. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvatatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance. Clin. Ther. 30, 1089-1101 (2008).
45. Hiro T, Kimura T, Morimoto T et al. Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome. J. Am. Coll. Cardiol. 54(4), 293-302 (2009).
46. Nakamura T, Obata JE, Kitta Y et al. Rapid stabilization of vulnerable carotid plaque within 1 month of pitavastatin treatment in patients with acute coronary syndrome. J. Cardiovasc. Pharmacol. 51(4), 365-371 (2008).
47. Morikawa S, Takabe W, Mataki C et al. The effect of statins on mRNA levels of genes related to inflammation, coagulation, and vascular constriction in HUVEC. J. Atheroscler. Thromb. 9(4), 178-183 (2002).
48. Jiang M, Bujo H, Zhu Y et al. Pitavastatin attenuates the PDGF-induced LR11/uPA receptor-mediated migration of smooth muscle cells. Biochem. Biophys. Res. Commun. 348, 1367-1377 (2006).
49. Kaneyuki U, Ueda S, Yamagishi S et al. Pitavastatin inhibits lysophosphatidic acid-induced proliferation and monocyte chemoattractant protein-1 expression in aortic smooth muscle cells by suppressing Rac-1-mediated reactive oxygen species generation. Vascul. Pharmacol. 46, 286-292 (2007).
50. Akisato Y, Ishii I. Effect of pitavastatin on macrophage cholesterol metabolism. Yakugaku Zasshi 128, 357-363 (2008).
51. Abe M, Matsuda M, Kobayashi H et al. Effects of statins on adipose tissue inflammation: their inhibitory effect on M YD 8 8 -indep endent IRF3/IFN b pathway in macrophages. Arterioscler. Thromb. Vasc. Biol. 28, 871-877 (2008).
52. Ohnaka K, Shimoda S, Nawata H et al. Pitavastatin enhanced BMP-2 and osteocalcin expression by inhibition of Rho-associated kinase in human osteoblasts. Biochem. Biophys. Res. Commun. 287(2), 337-342 (2001).
53. Han J, Zhou X, Yokoyama T, Hajjar DP, Gotto AM, Nicholson AC. Pitavastatin downregulates expression of the macrophage type B scavenger receptor, CD36. Circulation 109, 790-796 (2004).
54. Han J, Parsons M, Zhou X, Nicholson AC, Gotto AM, Hajjar DP. Functional interplay between the macrophage scavenger receptor class B type I and pitavastatin (NK-104). Circulation 110, 3472-3479 (2004).
55. Lamon BD, Summers BD, Gotto AM, Hajjar DP. Pitavastatin suppresses mitogen activated protein kinase-mediated Erg-1 induction in human vascular smooth muscle cells. Eur. J. Pharmacol. 606, 72-76 (2009).
56. Markle RA, Han J, Summers BD. Pitavastatin alters the expression of thrombotic and fibrinolytic proteins in human vascular cells. J. Cell. Biochem. 90, 23-32 (2003).
57. Nicholson AC, Hajjar DP, Zhou X, He W, Gotto AM, Han J. Anti-adipogenic action of pitavastatin occurs through the coordinate regulation of PPARg and Pref-1 expression. Br. J. Pharmacol. 151, 807-815 (2007).
58. Armitage J. The safety of statins in clinical practice. Lancet 370(9601), 1781-1790 .
59. Sattar N, Preiss D, Murray HM et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomized statin trials. Lancet 375(9716), 735-742 (2010).
60. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy of cholesterol- lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 371, 117-125 .
61. Ose L, Budinski D, Hounslow N, Arneson V. Long-term treatment with pitavastatin is effective and well tolerated by patients with primary hypercholesterolemia or combined dyslipidemia. Atherosclerosis 210(1), 202-208 (2010).
62. Ridker PM, Danileson E, Fonseca FA et al.; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 359(21), 2195-2207 (2008).
63. Product information. Lipitor (atorvastatin). Pfizer, NY, USA( 2009).
64. Product information. Lescol, Lescol XL (fluvastatin). Novartis Pharmaceuticals Corporation, NJ, USA (2006).
65. Product information. Mevacor (lovastatin). Merck, NJ, USA(2008).
66. Product information. Pravachol (pravastatin). Bristol-Myers Squibb, NJ, USA(2007).
67. Product information. Crestor (rosuvastatin). AstraZeneca, DE, USA (2010).
68. Product information. Zocor (simvastatin). Merck, NJ, USA(2008).
69. Clinicaltrials.govwww.clinicaltrials.gov